He Huang

103PUBLICATIONS
118CO-AUTHORS
Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (103)

|Jul 08, 2026
Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid Malignancies.

|Jul 03, 2026
CD7 chimeric antigen receptor T cells in patients with relapsed or refractory CD7-positive acute myeloid leukemia.

|Jul 02, 2026
Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B-ALL After CAR-T Therapy and HSCT: A Case Series.

|Jun 26, 2026
Peri-transplant TP53 molecular MRD as a prognostic biomarker of relapse in TP53-mutated AML/MDS undergoing allogeneic HCT.

|Jun 10, 2026
Iron-mediated ferroptosis impairs CAR-T cell function and antitumor efficacy.

|Jun 09, 2026
Peri-transplant molecular MRD monitoring by targeted NGS in patients with FLT3-ITD mutated acute myeloid leukemia.

Pageof 18

Frequent Collaborators

28 joint publications

Yi Luo

17 joint publications

Yongxian Hu

14 joint publications

Pengxu Qian

12 joint publications

Jimin Shi